Compositions comprising lipoteichoic acid for use in treating pleural effusion or pneumothorax
View Patent ↗The present invention relates to lipoteichoic acid T for use in treating pleural effusion or pneumothorax. The present invention also relates to the use of lipoteichoic acid T (LTA-T) in the manufacture of a medicament for treating pleural effusion or pneumothorax. The present invention also relates to a kit comprising a pharmaceutical composition comprising lipoteichoic acid T and instructions indicating that the composition is for use as a pleurodesis agent. In addition, the present invention relates to a method of treating pleural effusion or pneumothorax comprising administration of lipoteichoic acid T to a subject.
1. A method of treating pleural effusion or pneumothorax in a subject in need thereof comprising intrapleural administration of lipoteichoic acid T to the subject in a dosage of between 50 and 3000 micrograms.
2. The method of claim 1 wherein the subject is a mammal.
3. The method of claim 2 wherein the subject is a human.
4. The method according to claim 1 , wherein the lipoteichoic acid T is administered in combination with a further pleurodesis agent.
5. The method according to claim 2 , wherein the lipoteichoic acid T is administered in combination with a further pleurodesis agent.
6. The method according to claim 3 , wherein the lipoteichoic acid T is administered in combination with a further pleurodesis agent.
7. The method according to claim 4 , wherein the further pleurodesis agent is one or more agent selected from intrapleural talc, minocycline, Cornebacterium parvum, doxycycline, tetracycline, methylprednisolone acetate, fluorouracil, bleomycin, interferon-B, mitomycin-C, cisplatin, doxorubicin, transforming growth factor-beta (TGF-beta), quinacrine, 2% polydocanol, OK-432, Streptococcus pyogenes, fibrin tissue adhesive, povidone iodine, silver iodide, barium sulphate, plidocanol, etoposide and ipovidone.
8. The method according to claim 4 , wherein the further pleurodesis agent is selected from peptidoglycan, atypical LPS (lipopolysaccharide), MALP-2 and MALP-404 (lipoproteins), OspA, porin, antigen mixtures, LcrV, lipomannan, qlycosylphosphatidylinositol (GPI anchor), lysophosphatidylserine, lipophosphoglycan (LPG), zymosan, heat shock protein 60 (hsp60) and hemagglutinin.
9. The method according to claim 1 , wherein the lipoteichoic acid T is administered in the form of a pharmaceutical composition.
10. The method according to claim 1 , wherein the lipoteichoic acid T is administered in the form of a solution or suspension.
11. The method according to claim 1 , wherein the lipoteichoic acid T is administered in a dosage of between 250 micrograms and 3000 micrograms.
12. The method according to claim 1 , wherein the lipoteichoic acid T is administered in a dosage of between 300 micrograms to 400 micrograms.
13. The method according to claim 1 , wherein the lipoteichoic acid T is administered in a dosage of between 700 micrograms to 800 micrograms.
14. The method according to claim 1 , wherein the lipoteichoic acid T is administered in a dosage of between 900 micrograms to 1100 micrograms.
15. The method according to claim 1 , wherein the lipoteichoic acid T is administered in a dosage of between 1450 micrograms to 1550 micrograms.
16. The method according to claim 1 , wherein the dosage is administered in an amount of between 10-20 micrograms/kilogram body weight.
17. The method according to claim 1 , wherein the lipoteichoic acid T is administered in a dosage of between 50 micrograms to 550 micrograms.
18. The method according to claim 4 , wherein the lipoteichoic acid T and the further pleurodesis agent are administered simultaneously, separately and/or sequentially.
19. The method of claim 1 wherein the subject is a sheep, cow, pig, chicken, goat, cat, dog, or horse.
20. The method according to claim 1 , wherein the lipoteichoic acid T is administered after pneumothorax or pleural effusion has been resolved.